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Background and purpose: Traditionally, vaginal dose points have been deﬁned at the vaginal source level,
thus not providing dose information for the entire vagina. Since reliable vaginal dose volume/surface his-
tograms are unavailable, a strategy for comprehensive vaginal dose reporting for combined EBRT and BT
was established and investigated.
Material and methods: An anatomical vaginal reference point was deﬁned at the level of the Posterior–
Inferior Border of Symphysis (PIBS), plus two points ±2 cm (mid/introitus vagina). For BT extra points
were selected for the upper vagina at 12/3/6/9 o’clock, at the vaginal surface and 5 mm depth. A vaginal
reference length (VRL) was deﬁned from ring centre to PIBS. Fifty-nine patients treated for cervical cancer
were included in this retrospective feasibility study.
Results: The method was applicable to all patients. Total EQD2 doses at PIBS and ±2 cm were 36.7 Gy
(3.1–68.2), 49.6 Gy (32.1–89.6) and 4.3 Gy (1.0–46.6). At the vaginal surface at ring level doses were
respectively 266.1 Gy (67.6–814.5)/225.9 Gy (61.5–610.5) at 3/9 o’clock, and 85.1 Gy (55.4–140.3)/
72.0 Gy (49.1–108.9) at 12/6 o’clock. Mean VRL on MRI was 5.6 cm (2.0–9.4).
Conclusions: With this novel system, a comprehensive reporting of vaginal doses is feasible. The present
study has demonstrated large dose variations between patients observed in all parts of the vagina, result-
ing from different contributions from EBRT and BT.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 107 (2013) 99–105The worldwide established standard treatment for patients
with locally advanced (PFIGO stage IB2) cervical cancer is deﬁni-
tive radiotherapy in combination with chemotherapy. Intracavi-
tary brachytherapy (BT) plays an essential role in the curative
treatment. According to the gynaecological (GYN) GEC-ESTRO
guidelines [1,2] the D0.1 cm3 and D2 cm3 of the major organs at
risk (OAR), i.e. bladder, rectum and sigmoid, were suggested to
be reported at time of BT. Dose constraints for these OAR have been
reported and established for rectum and bladder [3,4]. However,
the clinical situation is different for the vagina as it is at the same
time target organ and organ at risk. Especially the upper vagina is
frequently treated to high doses, as it is directly adjacent to the
macroscopic tumour. In case of no or minimal involvement of the
vagina, however, there is no rationale to include large parts of
the non-adjacent part of the vagina.d Ltd. All rights reserved.
adiotherapy, Comprehensive
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sterveld).Vaginal morbidity after radiotherapy has not been extensively
investigated so far and the upper vagina has been referred to as
‘‘radioresistant’’ [5,6]. Nevertheless, it has been documented that
radiotherapy could lead to (sub-) mucosal changes like atrophy,
ﬁbrosis, telangiectasia and fragility, and as a consequence to short-
ening and tightening of the vagina. In addition, even ulceration,
necrosis and ﬁstulae may occur [5,7,8]. Fortunately, a low inci-
dence of severe vaginal toxicity Pgrade 3 of 1–7% has been re-
ported [6,9–12]. On the other side, sexual dysfunction,
diminished lubrication and pain during sexual intercourse, associ-
ated with a signiﬁcant impact on quality of life, are frequently re-
ported by patients after treatment for cervical cancer [13–15]. It
can be assumed that dose–effect relationships exist for both vagi-
nal morbidity and patient reported symptoms/quality of life. Only
one study has investigated the correlation between DVH parame-
ters (D2 cm3) and vaginal toxicity. However, no dose–effect rela-
tionships could be established for the upper vagina [16].
The assessment of the vaginal dose and dose distribution seems
to be challenging due to the large sensitivity for geometrical
changes in the high-dose regions of the upper vagina due to steep
dose gradients. In addition, uncertainties in the delineation and
100 Vaginal dose pointsreconstruction of small wall volumes are still unsolved problems in
the currently available treatment planning systems [17,18]. For
reproducible and comprehensive reporting of doses to different
longitudinal and circumferential parts of the vagina, a 3D vaginal
dose map, in analogy to that introduced for reporting rectal dose
distributions, has been suggested [19,20]. This vaginal dose map
takes into account the contribution of EBRT as well as of BT. How-
ever, such advanced 3D dose reporting is far from being introduced
into clinical practice. Thus, there is an urgent need for an easy-
applicable, reliable 2D/3D reporting method for the dose distribu-
tion throughout the vagina. However, the currently used vaginal
dose points at the surface and at 5 mm depth on the lateral surface
of the ring or ovoids [21,22] do not give a good representation of
the dose throughout the vagina. In addition, the surface points
are located in the steep dose gradient region. Since it remains un-
clear where the target structures for the individual vaginal morbid-
ity endpoints are located, additional dose points are needed at the
level of the vaginal sources as well as throughout the lower parts of
the vagina.
The aims of this study are:
 To ﬁnd a straightforward and reliable representation of the dose
throughout the vagina based on anatomic landmarks;
 To deﬁne dose points which can be used in both 2D (conven-
tional radiography) and 3D (CT or MRI) brachytherapy
planning;
 To establish a method which can be applied both for brachy-
therapy and external beam radiotherapy.
Material and methods
Sixty-ﬁve patients with cervical cancer FIGO stage IB2-IVA trea-
ted with deﬁnitive radiotherapy in the Department of Radiother-
apy of the Medical University of Vienna were included in the
present investigation. All patients participated in the EMBRACE
study between August 2008 and March 2012. The EMBRACE study
is an international prospective study on MRI-guided brachytherapy
in locally advanced cervical cancer (www.embracestudy.dk). Com-
plete datasets of 62 patients were available for analysis. Three
additional patients were excluded since they were treated with
pulse dose rate (PDR) brachytherapy.
All patients were treated with a combination of external beam
radiotherapy (EBRT) and intracavitary +/ interstitial needles
MRI-guided brachytherapy (BT). All patients were treated with a
tandem-ring applicator. The EBRT prescribed dose was 45 Gy in
25 fraction of 1.8 Gy. HDR brachytherapy was performed in four
fractions (in two applications) of 7 Gy. Details of this institutional
protocol are described in detail elsewhere [23].
For EBRT 3D based CT-assisted treatment planning and ﬂuoro-
scopic simulation was performed for all patients. A small radi-
opaque vaginal marker was inserted into the vagina to identify
the vaginal top and the anatomical vaginal length on CT (Fig. 1A).
For BT, orthogonal radiographs, CT and MRI with the applicator
in place were available in all patients. MRI was used for image
guided treatment planning, according to the GEC-ESTRO recom-
mendations [24].
The Posterior–Inferior Border of the pubic Symphysis (PIBS)
was chosen as an anatomic landmark as it is visible on radio-
graphs, CT (Siemens) and MRI (T2 SE, 0.2 T, Siemens) (Fig. 1A
and B). In addition, it represents the transition zone between
the lower and middle third of the vagina (E-appendix I) [25].
Gynaecologists classify the vagina into three parts: (1) the upper
third between the cervix and the level of the urethrovesical
junction; (2) the middle third between the level of the urethro-
vesical junction and the level of the PIBS and (3) the lower third
below the PIBS (Fig. 1A and B and E-appendix I) [25]. The PIBSvaginal dose point served as a reference to deﬁne several further
anatomical dose points along the vagina and also the vaginal ref-
erence length (VRL) (Fig. 1A and B). The PIBS vaginal dose point
was deﬁned 2 cm posterior from PIBS in the sagittal direction for
EBRT and for BT at the point of this line where it crosses the
applicator tandem (Fig. 1A). Additional vaginal dose points for
EBRT were selected for every centimetre (PIBS + 3 cm until
PIBS2 cm) and midVRL in the cranio-caudal body axis. For BT
the same vaginal dose points were taken on the tandem axis
which is assumed to represent the centre of the vagina. The
PIBS2 point was regarded as indicator of the vaginal introitus,
the PIBS + 2 point as indicator of the anatomical mid of the va-
gina [25]. The top of the vagina was depicted through the top
of the radio-opaque marker in EBRT and for BT at the intersec-
tion between tandem and intravaginal source, which is by deﬁ-
nition the centre of the ring.
For the high dose area at ring level additional dose points were
taken in the (para-transverse) application orientation at 3,6,9 and
12 o’clock (surface and 5 mm depth) (E-appendix II). The clockwise
circumferential assessment was also done in case of a measured
dose P4.5 Gy (70% of the prescribed dose) in the tandem axis
at the midVRL orP3.5 Gy (50% of the prescribed dose) at PIBS le-
vel. The length of the 85 and 60 Gy isodose lines was reported as
measured on a (para-)coronal MRI from the cervical os along the
vaginal axis until the 7 Gy and 3.5 Gy isodose lines, taking into ac-
count the total EBRT dose of 45 Gy (E-appendix II).
The vaginal reference length (VRL) was introduced as the dis-
tance between PIBS and the vaginal top to overcome the difﬁculty
of deﬁning the vaginal introitus, which is often not clearly identi-
ﬁable on images (Fig. 1B). In BT VRL was measured between the
PIBS and the ring centre. In addition, the distance from the centre
of the ring to the cervical os was measured. The VRL in BT is as-
sumed to provide a straightforward tool to assess the topography
of the implant and surrogate vaginal length. In EBRT the VRL was
measured at the mid-sagittal view of the multi-plane-reconstruc-
tion (MPR) of the planning CT.
The total dose was calculated by summing the total EBRT dose
and four times the BT fraction dose (in EQD23 Gy) for each point at
the same level (e.g. PIBS) for each patient by applying the linear
quadratic model (a/b = 3 Gy and T1/2 = 1.5 h) [26].
The lower parts of the vagina were not always visible in the
transverse view on the treatment planning system due to the MR
scanning protocol. To be able to interpolate missing dose data, a
dose proﬁle was designed which takes into account individual
VRL and loading pattern.
Descriptive statistics were used indicating mean, median, stan-
dard deviation and range.Results
Patient characteristics are shown in Table 1. Twenty-eight (48%)
of the patients had vaginal involvement to a greater or lesser ex-
tent. The median length of the vaginal involvement at diagnosis
was 17.5 mm (5–70). At time of the ﬁrst brachy-application, 12
(20%) patients still had vaginal involvement, however only one of
the patients had inﬁltration of the vagina to the lower third. The
median vaginal involvement at BT1 was 10 mm (10–60).
Median vaginal reference length (VRL) was 5.8 cm (3.0–8.7) on
the planning CT for EBRT. At time of BT, VRL was 6.1 cm (1.6–11.0)
on conventional radiographs and 5.6 cm (2–9.4) on MRI. The med-
ian distance from the centre of the ring to the cervical os was
0.5 cm (0.0–2.5).
Dose from EBRT, BT and summed dose in EQD23 Gy are shown in
Figs. 1A and 3 and E-appendix III. Almost all patients received full
EBRT dose from the vaginal top until PIBS + 2 level (Fig. 1A). A wide
Fig. 1. Deﬁnition of vaginal dose points and vaginal reference length (VRL). (A) Vaginal dose points are deﬁned in relation to a point at the level of the posterior–inferior
border of the symphysis (PIBS) on sagittal (reconstructed) CT or MR images used for EBRT and BT treatment planning. The star at PIBS level represents the vaginal reference
point. In the table on the right side mean (SD) and median (min–max) values are given for each level in EBRT and for total dose in EQD2. Additionally, total doses to the top are
given for all four clockwise positions at the vaginal surface and 5 mm depth (e.g. median total dose at 3 o’clock is respectively 266 and 115 Gy for surface and 5 mm depth).
(B) VRL at time of BT with a ring applicator in situ on a lateral radiograph, sagittal MPR CT image and sagittal MRI view. VRL is measured from centre of the ring (indicated by a
star) to the PIBS level, indicated by the solid line orthogonal to the body axis.
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location of the ﬁeld border. The ﬁeld border was on average located
0.5 cm caudal from the PIBS, ranging from 2 cm cranial to 4 cm
caudal.Regarding the dose to the upper vagina at time of BT, dose to the
lateral vaginal surface was 2–3 times higher than to the anterior
and posterior wall (Fig. 1A). Although known steep dose gradients
at the vaginal surface at ring level, a good correlation between the
Table 1
Patient characteristics (n = 59).
Mean age (range) 55 (32–82)
FIGO stage (n, %)
IB 4 (7)
II 43 (73)
III 10 (17)
IVA 2 (3)
Vaginal involvement at time of diagnosis (n, %)
No 31 (52)
Upper third 21 (36)
Middle third 6 (10)
Lower third 1 (2)
Vaginal involvement at BT1 (n, %)
No 47 (80)
Upper two-third 11 (18)
Middle third 0 (0)
Lower third 1 (2)
Bulky disease (>4 cm) (n, %)
No 17 (29)
Yes 42 (71)
Histology (n, %)
Squamous cell carcinoma 51 (86)
Adenocarcinoma 7 (12)
Other 1 (2)
EBRT techniques (n, %)
4-Field box 54 (92)
IMRT 5 (8)
BT with interstitial needles (n, %)
No 24 (41)
Yes 35 (59)
102 Vaginal dose pointssurface and 5 mm depth vaginal dose at the upper vagina was seen
(E-appendix IV). However, standard deviations were much smaller
at 6/12 o’clock than at 3/9 o’clock (Fig. 1A).
Fourteen patients (24%) received a physical dose ofP4.5 Gy per
fraction to the vaginal surface at midVRL level (E-appendix V). In
these patients, median doses up to 96.9 Gy (55.4–212.1) in
EQD23 Gy were seen at midVRL level, approximately corresponding
to PIBS + 2 (data not shown). One of these patients had vaginal
involvement of the lower third of the vagina (IIIA) with substantial
residual disease at time of BT. The other thirteen patients had
either no involvement (n = 7) or upper third involvement (IIA:
n = 6) with small residual vaginal disease at time of BT. The VRL
of these patients was 3.4 cm (2.0–5.2), which is 2.2 cm shorter than
the VRL of the entire group.
Five patients (8.5%) received a dose of 3.5 Gy or higher to the
vagina in the transitional zone from the middle to the lower third
part (PIBS level). The median dose in these patients was 4.5 Gy
(4.0–4.8) per fraction and total median dose in EQD23 Gy 48.3 Gy
(40.5–68.2). The median VRL was 2.4 cm (2.0–3.0). The median dis-
tance from cervical os to ring centre was 1.2 cm (0.5–2.6), which is
0.7 cm longer than the median length in the entire group.
The median length of the 85 Gy and 60 Gy isodose lines was
2.0 cm (1.0–3.0) and 3.0 cm (1.7–3.7), respectively.Discussion
To date, despite frequently reported vaginal morbidity like dry-
ness and sexual dysfunction, there is limited awareness of the vag-
inal dose in cervical cancer patients treated with deﬁnitive radio
(chemo)therapy. Information on the dose to the mid or lower parts
of the vagina is usually completely lacking, despite suggestions in
literature that the lower part may be even more vulnerable to irra-
diation than the upper third of the vagina [5]. It therefore seems to
be logical – in particular in the era of fast developing image guided
radiotherapy – to relate vaginal morbidity to detailed and compre-
hensive dose volume information throughout the whole vagina.
However, 3D DVH analysis has been shown to be critical to the va-
gina due to both major contouring and dosimetric uncertainties[17]. In addition, dose volume/surface histograms are not available
in the current brachytherapy treatment planning systems.
In order to improve this unsatisfactory situation within a clini-
cally meaningful context, a straightforward easily applicable 2D
point dose reporting method throughout the whole vagina has
been introduced. An anatomical vaginal reference point, located
2 cm posterior from the Posterior–Inferior Border of the Symphysis
(PIBS) was introduced. This PIBS reference point indicates the tran-
sitional zone from lower to middle third of the vagina according to
long standing gynaecologic knowledge [25]. This pelvis diaphragm
level also indicates the location of part of the clitoris and the anal
sphincter [27]. The dose to the vaginal introitus and to the mid of
the vagina can be calculated starting from this reference point. It
was selected as respectively 2 cm below and above PIBS level.
The level of the mid vagina also represents the region of the vesi-
co-urethral junction (E-appendix I) [25]. Dose points in the upper
vagina were selected along the long standing MD Anderson and
ABS tradition at the level of the vaginal sources (ring level)
[21,22] and extended to the positions at 12 and 6 o’clock in order
to assess the dose inhomogeneity in the upper vagina. No extra
dose points for the upper vagina were selected for EBRT as dose
was assumed to be represented by the target dose. Our experience
suggests this method as a straightforward easily applicable clinical
method by which a dose proﬁle throughout the entire vagina can
be obtained for the individual patient (Fig. 2).
In most patients the EBRT dose was at least 95% of the pre-
scribed dose (45 Gy) for the upper two-third of the vagina. This
is due to the fact that the upper half of the vagina is included in
the CTV for EBRT. Due to PTV margins of 1–2 cm, the lower border
of the EBRT ﬁeld is on average located 0.5 cm below the PIBS. This
can also be assumed for 2D EBRT in general, since the caudal ﬁeld
border along long standing traditions is placed at the lower border
of the obturator foramina which is at the level of the PIBS [22,28].
BT doses are very high in the upper vagina with large dose var-
iation. They are most pronounced in the lateral parts when using
the ring applicator with median surface doses of 15.3 and
13.7 Gy (left/right). The contribution of BT is smaller in the lower
parts of the vagina, but nevertheless may become considerable in
some individual patients with maximum doses per fraction up to
6.4 Gy in the anatomical mid vagina (PIBS + 2), 4.8 Gy at PIBS and
2.7 Gy at introitus level.
The sum of the EBRT and BT doses provides a good overview of
the dose throughout the vagina. For the anatomical mid vagina
(PIBS + 2) median dose in the centre of the vagina was 50 Gy,
mainly coming from EBRT (Figs. 1A and 3). However, the variation
is signiﬁcant with maximum doses of 90 Gy (Figs. 1A and 3). For
the transition zone from middle to low vagina (PIBS level), the
median total dose is 37 Gy with the major contribution from EBRT,
which is also true for the vaginal introitus level (median 4 Gy)
(Figs. 1A and 3). For both levels a considerable dose variation has
been seen with maximum doses of 68 and 47 Gy for PIBS and
PIBS2 level, respectively. This variation may come from both
EBRT and BT (Fig. 1A, E-appendix III).
Patients with vaginal involvement of the middle or lower third
of the vagina (extensive stage IIA, IIIA) receive an intermediate to
high dose to the whole vagina due to external beam radiotherapy
and in case of residual disease at the time of BT due to additional
treatment by BT. Consequently, these patients have a higher
chance of entire vaginal occlusion or other grade 3 or 4 vaginal tox-
icities compared to those patients without extensive (residual)
vaginal involvement. In addition, if the vaginal reference length
is relatively short (VRL <4 cm), the middle third of the vagina also
receives a high dose which may even spread to the lower third.
Interestingly, adjacent structures like bladder neck, urethra, ano-
rectal region and clitoris also receive a signiﬁcant dose under these
circumstances. The same is true if the applicator cannot be placed
Fig. 2. Vaginal dose proﬁle for two different cases showing the contribution of EBRT and BT dose to the total dose in EQD2. The x-axis starts at the upper vaginal surface and
continues in caudal direction along the central axis of the vagina. PIBS and PIBS+/2 cm points are shown. At the level of the ring source path, a point at the applicator surface
(red) and in 5 mm depth (green) is indicated. The left case had dose values as well as a VRL closest to the median values of all analysed cases and is therefore illustrate a
representative situation. The lower ﬁeld border of EBRT is located close to PIBS, at a distance of 5.4 cm from the upper vaginal surface. The right case shows a situation with
PIBS very close to the ring applicator. Deﬁnition of PIBS + 2 cm is not applicable anymore. EBRT dose is substantially higher at PIBS as well as PIBS2 cm compared to the
‘‘median’’ case at the left. (For interpretation to colours in this ﬁgure, the reader is referred to the web version of this paper.)
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this part of the vagina were seen in almost one quarter of our pa-
tients. Only 7/14 patients had vaginal involvement and the major-
ity of them (6/7) limited to the upper third at time of BT.
As long as 3D vagina assessment tools such as vaginal dose
maps or vaginal surface histograms are not incorporated into the
currently available treatment planning systems and basic difﬁcul-
ties with the thin vaginal wall delineation are not solved, vaginal
dose points should be used as surrogate for evaluation of the spa-
tial dose distribution in the upper vagina, and the dose in the mid-
dle and lower parts of the vagina. In EBRT and BT the doses at the
PIBS and PIBS ± 2 cm levels should be reported to achieve an over-
all dose proﬁle for the lower half of the vagina, since these levels
correspond to important anatomic levels of the vagina, namely
the transitional zones to respectively the mid and lower third of
the vagina (E-appendix I). In addition, for EBRT especially PIBS
and PIBS2 cm seem to be important to report, because these
points give an estimation of the location of the ﬁeld border and
consequently an indication if the entire vagina is irradiated or
not (Fig. 1A and 3). Furthermore, for BT especially the dose at PIBS
and PIBS + 2 cm seems important to indicate the location of the
transitional zone from very high to intermediate dose (Figs. 1A
and 2 and E-appendix III). In BT the following additional dose
points should be reported at the level of the vaginal sources,
namely at 12, 3, 6 and 9 o’clock at the surface and 5 mm depth
(Fig. 3). Due to uncertainties of the exact location of the vaginalsource and/or wall and steep dose fall-off nearby the sources, the
surface dose points seem to be more prone to uncertainties in dose
assessment than the 5 mm depth dose points. Standard deviations
of the dose at 5 mm depth are small and thus perhaps better pre-
dictors for vaginal toxicity. This should however be investigated in
a prospective vaginal morbidity study.
Although the anatomy of the vagina is different during EBRT
from BT due to vaginal packing, vaginal reference length did not
differ at time of EBRT and BT. This is probably due to different
methods for indicating the vaginal top (posterior fornix in EBRT
versus cervical os in BT). Vaginal packing mainly stretches the va-
gina in lateral direction in the mid part of the vagina. Conse-
quently, doses from EBRT and BT to the vaginal top, PIBS and
PIBS2 cm can be safely summed. There are however some uncer-
tainties about the PIBS + 2 cm level. In addition, some uncertainties
are present about the dose to the vagina during EBRT. It is known
that, at least in postoperative patients, the vagina can move consid-
erably [29].
In conclusion, the suggested vaginal dose points and length
measurements can be easily introduced in clinical practice and
provide an overview of the spatial dose distribution resulting from
EBRT and BT in the upper vagina and the dose in the middle and
lower vagina. We also have shown that these dose points are dis-
tinctive, since considerable differences are revealed in the study
patient population despite using a ﬁxed institutional protocol. Fur-
ther research is needed to investigate if the proposed dose points
Fig. 3. Para-sagittal and para-transverse schematic representation for ring and ovoid applicator of the recommended vaginal dose points (yellow dots) at time of EBRT and BT.
Four levels are indicated (mentioned in cranial-to-caudal direction): (1) vaginal top level which represents the level at the intersection of the intrauterine source and the
centre of the ring or ovoid sources along the vaginal source axis; (2) PIBS + 2 which represents the anatomical mid of the vagina (3) PIBS level which represents the
transitional zone from mid to lower third of the vagina and (4) PIBS-2 level which represents the introitus level. On the right side of the schematic EBRT ﬁgure the dose
gradient along the vaginal axis is shown. On the right side of the schematic BT ﬁgure the median total doses in each recommended dose point is given. (For interpretation to
colours in this ﬁgure, the reader is referred to the web version of this paper.)
104 Vaginal dose pointsare applicable and useful for different applicators, different plan-
ning systems and different dose rates within various institutional
protocols. Ultimately, such points may contribute to ﬁnd dose–ef-
fect relationships when correlated to various vaginal morbidity
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